Biocryst Pharmaceutical’s Revenue by Segment (2016-2022)

You need Pro Plan to access KPI data.

Get 60% off on Pro

Discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

.

About

This statistic highlights Biocryst Pharmaceutical’s revenue by segment from Q1 2016 onwards, split across Collaborative and other Research and Development, Product Sales and Royalty Revenue segments.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information

Subscribe to Pro or Enterprise plans to unlock this feature.

Contact the Analyst

Subscribe to Pro or Enterprise plans to unlock this feature.

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Biocryst Pharmaceutical’s revenue by segment from Q1 2016 onwards, split across Collaborative and other Research and Development, Product Sales and Royalty Revenue segments.

Biocryst Pharmaceutical’s Revenue by Segment

Segments  Q3 2020 Q2 2021 Q3 2021 Contribution in Q3 2021
Collaborative and other research and development 3.37 1.4 1.53 4%
Product Sales 2.48 33.43 39.14 95%
Royalty revenue 0.25 0.13 0.32 1%
Total 6.1 34.96 40.99 100%

(All figures in millions, except percentages)

Biocryst Pharmaceuticals’ revenue in Q3 2020 was $6.1 million, which multiplied by almost 6 times in Q3 2021 and rose to $40.99 million. Quarterly, the company observed a revenue growth of 17.2% as compared to $34.96 million in Q2 2021 to $40.99 million in Q3 2021.

Further, the revenue can be bifurcated into the following segments:

Collaborative and other Research and Development

There are various third-party firms or organizations, with which Biocryst has license agreements or collaborations. Apart from these, the company even has Research and Development agreements with multiple government entities for the manufacture of medicines or drugs. This is known as the Collaborative and other Research Development segment.

Trends Observed

  • This segment earned a revenue of $1.53 million in Q3 2021, which consisted of 4% of the company’s total revenue.
  • In Q3 2020, the revenue from this segment was $3.37 million and contributed 55% to the total revenue; but by Q3 2021, it fell by approx. 54.5%.
  • Quarterly, there was a growth as the revenue increased by 9% from $1.4 million in Q2 2021.

Product Sales

Product sales refer to the selling of medicine or oral drugs and other commodities provided by the firm.

Trends Observed

  • The Product Sales segment accounted for 95% of the company’s total revenue in Q3 2021, worth $39.14 million.
  • In Q3 2020, this segment incurred a revenue of $2.48 million, which went up by more than 10 times in Q3 2021, to $39.14 million.
  • On a QoQ basis, the segment observed a growth of approximately 17% as compared to $33.43 million in Q2 2021.

Royalty Revenue

This segment includes the revenue earned by Biocryst Pharmaceuticals from patents of various medicines/drugs the company produces, with other pharmaceutical companies like Shinogi or Green Cross.

Trends Observed

  • Royalty Revenue segments revenue in Q3 2021 was $0.32 million, which was 1% of the total revenue.
  • On a YoY basis, the revenue went up by 25% from $0.25 million in Q3 2020.
  • Quarterly, in Q2 2021, the segment revenue was $0.13 million which multiplied approximately 1.5 times to $0.32 million in Q3 2021.

About the Company

Found in 1986, BioCryst Pharmaceuticals Inc. is a US-based pharmaceutical company. It is headquartered in North Carolina and focuses on producing oral drugs for serious and rare diseases or illness. The firm masters in clinical development, regulatory affairs and drug discovery. With this, they are even progressing at advancing such clinical programs and generation of new compounds from the company’s discovery engine.

Did you like Biocryst Pharmaceutical’s revenue by segment statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount until Sunday

Pro

$19
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Billed annually, local taxes extra. 

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount on Annual plan

Pro

$49
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.